KYTX vs SCTX: stock comparison and AI forecast
Kyverna Therapeutics, Inc. (KYTX) and Scribe Therapeutics, Inc. (SCTX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
KYTX Kyverna Therapeutics, Inc.
- Market Cap
- $302M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
SCTX Scribe Therapeutics, Inc.
- Market Cap
- $297M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- KYTX and SCTX have similar market capitalizations ($302M and $297M).
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | KYTX | SCTX |
|---|---|---|
| Market Cap | $302M | $297M |
| P/B Ratio | 1.82x | – |
| EPS | $-2.27 | – |
| Book Value/Share | $2.68 | – |
Profitability & Margins
| Metric | KYTX | SCTX |
|---|---|---|
| ROE | -92.2% | – |
| ROA | -69.4% | – |
| ROIC | -80.7% | – |
Financial Health
| Metric | KYTX | SCTX |
|---|---|---|
| Current Ratio | 9.06x | 0.57x |
| D/E Ratio | 0.33x | – |
| Financial Leverage | 1.33x | – |
| Interest Coverage | -69.0x | -10.7x |
| Working Capital | $184M | -$34M |
Cash Flow
| Metric | KYTX | SCTX |
|---|---|---|
| Operating Cash Flow | -$159M | – |
Income Statement
| Metric | KYTX | SCTX |
|---|---|---|
| Operating Income | -$159M | – |
| Net Income | -$153M | – |
| R&D Expense | $115M | – |
Dividend & Shareholder Information
| Metric | KYTX | SCTX |
|---|---|---|
| Shares Outstanding | 62M | 19M |
KYTX vs SCTX: stock comparison and AI forecast
Which is bigger, KYTX or SCTX?
KYTX and SCTX have similar market capitalizations ($302M and $297M).
Which one does Intratio's AI model rank higher, KYTX or SCTX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.